TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity

BACKGROUND: Patients with diabesity have a significantly increased risk of developing cardiovascular disease. Therefore, therapy addressing the multiple metabolic abnormalities linked with diabesity and leading to further reduction of cardiovascular risk is highly desirable. Activation of the TGR5 r...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zambad, Shitalkumar P, Tuli, Davinder, Mathur, Anoop, Ghalsasi, Sameer A, Chaudhary, Anita R, Deshpande, Shailesh, Gupta, Ramesh C, Chauthaiwale, Vijay, Dutt, Chaitanya
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3873233/
https://ncbi.nlm.nih.gov/pubmed/24379686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S50209
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares